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Chikungunya Virus
Infection in
Traveler to
Australia
To the Editor: Chikungunya is a
mosquitoborne alphavirus in the fam-
ily  Togaviridae. Recently, a chikun-
gunya virus epidemic that affected
thousands of persons occurred in
islands in the southwestern Indian
Ocean, including Mauritius and
Reunion (1). An outbreak is ongoing
in India, and cases are being exported
to many other countries (2–4) The
likelihood of importation of exotic
infectious agents into Australia
increased during events such as the
March 2006 Commonwealth Games
in Melbourne. Urgent diagnosis of
rarely seen infections is a travel health
challenge, particularly when serologic
tests used for diagnosis in areas with
high prevalence are not locally avail-
able. Only 1 previously diagnosed
case of chikungunya virus infection
has been reported in Australia; it
involved importation of the virus
from Indonesia to Darwin in 1989 (5).
We report a second case of infection
with this virus.
A59-year-old man came to a hos-
pital emergency department in North
Melbourne, Australia, on March 12,
2006, 5 days after traveling from
Mauritius for the Commonwealth
Games. He reported a 2-day history of
acute swelling and erythema of the
left leg and associated malaise.
Twenty-four hours earlier, severe
lumbar back pain and arthralgias that
involved the lower limbs had devel-
oped, with associated fevers, rigors,
and headache.
The patient had a temperature of
39°C, bilateral conjunctivitis, tender
and markedly swollen Achilles ten-
dons, a swollen left ankle, and a mac-
ulopapular rash that involved the left
forefoot and anterior portion of the
shin. Initial blood examinations
showed leukopenia (leukocyte count
1.8 × 109/L, lymphocyte count 0.2 ×
109/L), mild thrombocytopenia
(platelet count 105 × 109/L), and
abnormal liver function test results
(alanine aminotransferase 133 IU/µL,
γ-glutamyl transpeptidase 141 IU/µL,
bilirubin 7 mmol/L). Malaria blood
films and dengue serologic results
were negative. A validated, in-house,
generic alphavirus reverse transcrip-
tion–PCR (RT-PCR) showed positive
results 24 hours after collection of
blood when the patient was admitted.
The patient received supportive
treatment and was discharged from
the hospital 3 days after admission, at
which time leukopenia and thrombo-
cytopenia had improved. The patient
had fully recovered on review 1 week
after discharge.
For virus isolation, plasma and
leukocyte fractions were placed onto
Vero E6 cells and incubated at 37°C
for 5 days. Cells were observed daily
for virus-specific cytopathic effects. A
virus isolate was obtained after 4 days
of cell culture. A 10-mL volume of
supernatant from infected cells was
applied to a carbon-coated grid,
stained with phototungstic acid, and
examined by electron microscopy.
This procedure showed virus with
morphology similar to Togavirus
(data not shown).
Chikungunya virus was identified
by a heminested RT-PCR for the non-LETTERS
structural protein 4 gene. First-round
primers were AlphaF1 (GenBank
accession no. NC004162, nt
6942–6961, 5′-CSATGATGAARTC
HGGHATG-3′) and AlphaR (nt
7121–7141, 5′-CTATTTAGGACCRC
CGTASAG-3′). Second-round primers
were AlphaF2 (nt 7480–7501) (5′-
TGGNTBAAYATGGAGGTIAAG-
3′) and AlphaR. Sequencing of the
second-round product identified the
virus. A 339-bp fragment (GenBank
accession no. DQ678928) had 97%
identity with the African prototype
strain S27 isolated in Tanzania
(Tanganyika) in 1953 (AF369024) and
100% identity with viral sequences
from Reunion Island in 2006
(DQ443544).
Knowledge of distant epidemics
aids clinical recognition of infections
not commonly seen in Australia.
Websites and electronic bulletins
(e.g., Promed) are a conduit of infor-
mation. On the basis of this case-
patient, those in Australia became
more aware of the chikungunya virus
epidemics affecting the islands of the
southwestern Indian Ocean.
Laboratory diagnosis of chikun-
gunya virus infection is usually sero-
logic. However, alphavirus infections
not endemic to Australia are unlikely
to be diagnosed serologically because
specific assays are generally available
only for those viruses known to circu-
late in Australia. Because viremia of
alphaviruses is brief, success of RT-
PCR depends on early admission and
clinical recognition of infection (6).
Rapid establishment of a defini-
tive diagnosis had substantial benefits
that included management of the
febrile patient, reduced need for fur-
ther investigations, and better progno-
sis. Infection caused by an introduced
arbovirus may have important public
health implications in Australia.
Because immunity in the Australian
population is unlikely, consideration
must be given to the potential for
transmission of the virus to caregivers
and the local community. chikungun-
ya virus is commonly spread by mos-
quitoes of the genera Aedes, including
Aedes aegypti,  Ae.  furcifer-taylori,
Ae. luteocephalus, Ae. albopictus, and
Ae. dalzieli (7). The Australian Ross
River and Barmah Forest alphaviruses
are spread by many species of Aedes
and  Culex (8). Because some local
species could transmit chikungunya
virus, necessary steps should be taken
to ensure containment when a patient
is viremic.
This case highlights the potential
for exotic viruses to be introduced
into Australia by visitors or returning
travelers and the utility of molecular
testing for their rapid detection. The
generic nature of the RT-PCR enabled
detection of an alphavirus with subse-
quent specific identification by
sequencing. Rapid identification and
differentiation in a public health set-
ting minimized the potential for
spread of the virus.
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Avian Influenza A
(H5N1) Age
Distribution in
Humans
To the Editor: A total of 229
confirmed human cases of avian
influenza A (H5N1) were reported to
the World Health Organization
(WHO) from 10 countries of Africa,
Asia, and Europe in the 30 months
leading up to July 4, 2006 (1). WHO
has highlighted the skewed age distri-
bution of these confirmed cases
toward children and young adults,
with relatively few cases in older age
categories (2). An explanation for this
age bias is currently lacking,
although a range of behavioral, bio-
logical, demographic, and data-relat-
ed factors may account for the
observed pattern (2,3). 
To determine whether the statisti-
cal parameters of the case distribution
can shed any light on the issue, we
reviewed the age profile of patients
with confirmed avian influenza A
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